Get notified when SMNR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Controlled Company (new) — Scilex Holding Company controls over 80% of voting power, giving it control over all stockholder votes including director elections and major corporate decisions.
- Going Concern (new) — Substantial doubt persists given cash of only $0.1M and operating cash outflow of $2.3M against minimal liquidity; the reported $154.3M net loss is overwhelmingly non-cash (Business Combination charges), not cash burn.
- Material Weakness (new) — Material weaknesses identified in internal control over financial reporting related to carve-out financial statement preparation and stock-based compensation expense.
- Single Product / Concentration (new) — Company has only one product candidate (SP-102) in development; no approved products, no revenue, and no alternative pipeline if SP-102 fails to gain approval or achieve commercial success.
- Cryptocurrency Treasury Strategy (unchanged) — Filing maintains a standing Risks Related to Cryptocurrency disclosure for a named Bitcoin treasury/financing strategy that has not been implemented or tested (1940-Act risk). On minimal cash with going-concern doubt, this non-standard treasury pivot is material even when a related financing line moves out of Recent Developments.
Semnur Pharmaceuticals secondary offering of up to 12.85M warrants by selling stockholders; company receives no proceeds from resale
Filed December 29, 2025 · ~3 min read
Key Changes
-
high
Secondary offering by selling stockholders of up to 12,850,000 warrants and underlying shares; Semnur receives zero proceeds from the resale. Company may receive up to $100.7M only if warrant holders exercise for cash (not guaranteed).
The Offering / Use of Proceeds view on EDGAR → -
high
Scilex Holding Company controls over 80% of outstanding common stock, giving it control over all stockholder votes including director elections and major corporate decisions.
The Offering / Risk Factors view on EDGAR → -
high
GAAP net loss of $154.3M for the nine months ended September 30, 2025 (vs. $3.9M prior year), driven overwhelmingly by non-cash SPAC/Business Combination charges; operating cash outflow was only $2.3M. Cash on hand: $0.1M.
Management's Discussion and Analysis verify on EDGAR →
7 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FUL 10-Q) is open in full — no account needed.
Partner
Trade SMNR commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 27, 2026 · How we verify